HEPION PHARMACEUTICALS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
HEPION PHARMACEUTICALS, INC. (HEPA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $20.78 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- HEPION PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-03-31 was $20.78K, a 97.06% decline year-over-year.
- HEPION PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-09-30 was $28.63K, a 91.02% decline year-over-year.
- HEPION PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-06-30 was $28.63K, a 91.43% decline year-over-year.
- HEPION PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-03-31 was $705.77K, a 31.40% increase year-over-year.
- HEPION PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $20.78K, a 97.37% decline from fiscal 2024.
- HEPION PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $791.64K, a 40.94% decline from fiscal 2023.
- HEPION PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.34M, a 41.31% decline from fiscal 2022.
- HEPION PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $2.28M, a 24.67% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2025-12-31 | $20.78K 10-K · filed 2026-03-12 | |||
| 2025-03-31 | $20.78K 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $791.64K 10-K · filed 2026-03-12 | |||
| 2024-09-30 | $28.63K 10-Q · filed 2025-11-12 | $57.25K derived: sum of 2 quarters · filed 2025-11-12 | $763.02K derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $28.63K 10-Q · filed 2025-11-12 | $734.39K derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $705.77K 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $1.34M 10-K · filed 2025-04-08 | |||
| 2023-09-30 | $318.91K 10-Q · filed 2024-11-14 | $652.87K derived: sum of 2 quarters · filed 2024-11-14 | $1.19M derived: sum of 3 quarters · filed 2024-11-14 | |
| 2023-06-30 | $333.95K 10-Q · filed 2024-11-14 | $871.08K derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2023-03-31 | $537.12K 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | $2.28M 10-K · filed 2024-04-16 | |||
| 2022-09-30 | $546.58K 10-Q · filed 2023-11-20 | $1.18M derived: sum of 2 quarters · filed 2023-11-20 | $1.74M derived: sum of 3 quarters · filed 2023-11-20 | |
| 2022-06-30 | $634.65K 10-Q · filed 2023-11-20 | $1.19M derived: sum of 2 quarters · filed 2023-11-20 | ||
| 2022-03-31 | $556.61K 10-Q · filed 2023-11-20 | |||
| 2021-12-31 | $3.03M 10-K · filed 2023-04-10 | |||
| 2021-09-30 | $1.19M 10-Q · filed 2022-11-14 | $2.00M derived: sum of 2 quarters · filed 2022-11-14 | $2.96M derived: sum of 3 quarters · filed 2022-11-14 | |
| 2021-06-30 | $811.95K 10-Q · filed 2022-11-14 | $1.77M derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2021-03-31 | $957.87K 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $2.38M 10-K · filed 2022-04-08 | |||
| 2020-09-30 | $1.38M 10-Q · filed 2021-11-15 | $1.39M derived: sum of 2 quarters · filed 2021-11-15 | $1.39M derived: sum of 3 quarters · filed 2021-11-15 | |
| 2020-06-30 | $4.12K 10-Q · filed 2021-11-15 | $12.37K derived: sum of 2 quarters · filed 2021-11-15 | ||
| 2020-03-31 | $8.25K 10-Q · filed 2021-11-15 | |||
| 2019-12-31 | $66.18K 10-K · filed 2021-03-31 | |||
| 2019-09-30 | $17.13K 10-Q · filed 2020-11-16 | $34.26K derived: sum of 2 quarters · filed 2020-11-16 | $51.77K derived: sum of 3 quarters · filed 2020-11-16 | -$146.75K derived: sum of 4 quarters · filed 2020-11-16 |
| 2019-06-30 | $17.13K 10-Q · filed 2020-11-16 | $34.64K 10-Q · filed 2019-08-14 | -$163.88K derived: sum of 3 quarters · filed 2020-11-16 | -$101.00K derived: sum of 4 quarters · filed 2020-11-16 |
| 2019-03-31 | $17.51K 10-Q · filed 2020-11-16 | -$181.02K derived: sum of 2 quarters · filed 2020-11-16 | -$118.14K derived: sum of 3 quarters · filed 2020-11-16 | $34.63K derived: sum of 4 quarters · filed 2020-11-16 |
| 2018-12-31 | -$198.52K derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-14 | -$135.64K derived: sum of 2 quarters · filed 2020-05-14 | $17.12K derived: sum of 3 quarters · filed 2020-05-14 | $234.51K 10-K · filed 2020-05-14 |
| 2018-09-30 | $62.88K 10-Q · filed 2019-11-14 | $215.65K derived: sum of 2 quarters · filed 2019-11-14 | $433.03K 10-Q · filed 2018-11-14 | $787.63K derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | $152.76K 10-Q · filed 2019-08-14 | $370.15K 10-Q · filed 2019-08-14 | $724.75K derived: sum of 3 quarters · filed 2019-11-14 | $1.12M derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-03-31 | $217.39K 10-Q · filed 2019-11-14 | $571.98K derived: sum of 2 quarters · filed 2019-11-14 | $963.13K derived: sum of 3 quarters · filed 2019-11-14 | $1.24M derived: sum of 4 quarters · filed 2019-11-14 |
| 2017-12-31 | $354.60K derived: 10-K 6 month − 10-Q 3 month · filed 2019-03-14 | $745.74K 10-K · filed 2019-03-14 | $1.02M derived: sum of 3 quarters · filed 2019-03-14 | $1.57M derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-09-30 | $391.14K 10-Q · filed 2017-11-14 | $664.37K derived: sum of 2 quarters · filed 2019-03-14 | $1.22M derived: sum of 3 quarters · filed 2019-03-14 | $1.70M derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-06-30 | $273.23K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $827.70K derived: sum of 2 quarters · filed 2019-03-14 | $1.31M derived: sum of 3 quarters · filed 2019-03-14 | $1.76M 10-K · filed 2019-03-14 |
| 2017-03-31 | $554.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-04-12 | $1.04M derived: sum of 2 quarters · filed 2017-04-12 | $1.48M 10-Q · filed 2017-04-12 | $1.91M derived: sum of 4 quarters · filed 2018-03-26 |
| 2016-12-31 | $483.73K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-14 | $928.68K 10-Q · filed 2017-02-14 | $1.36M derived: sum of 3 quarters · filed 2018-03-26 | $1.59M derived: sum of 4 quarters · filed 2018-03-26 |
| 2016-09-30 | $444.96K 10-Q · filed 2016-11-14 | $873.74K derived: sum of 2 quarters · filed 2018-03-26 | $1.10M derived: sum of 3 quarters · filed 2018-03-26 | $1.34M derived: sum of 4 quarters · filed 2018-03-26 |
| 2016-06-30 | $428.78K derived: 10-KT 12 month − 10-Q 9 month · filed 2018-03-26 | $656.48K derived: sum of 2 quarters · filed 2018-03-26 | $890.96K derived: sum of 3 quarters · filed 2018-03-26 | $901.87K 10-KT · filed 2018-03-26 |
| 2016-03-31 | $227.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-13 | $462.18K derived: sum of 2 quarters · filed 2016-05-13 | $473.08K 10-Q · filed 2016-05-13 | $1.40M derived: sum of 4 quarters · filed 2016-09-28 |
| 2015-12-31 | $234.47K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-12 | $245.38K 10-Q · filed 2016-02-12 | $1.17M derived: sum of 3 quarters · filed 2016-09-28 | $1.85M derived: sum of 4 quarters · filed 2016-09-28 |
| 2015-09-30 | $10.91K 10-Q · filed 2015-11-12 | $940.11K derived: sum of 2 quarters · filed 2016-09-28 | $1.62M derived: sum of 3 quarters · filed 2016-09-28 | $2.02M derived: sum of 4 quarters · filed 2016-09-28 |
| 2015-06-30 | $929.20K derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-28 | $1.61M derived: sum of 2 quarters · filed 2016-09-28 | $2.01M derived: sum of 3 quarters · filed 2016-09-28 | $2.12M 10-K · filed 2016-09-28 |
| 2015-03-31 | $677.92K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-14 | $1.08M derived: sum of 2 quarters · filed 2015-05-14 | $1.19M 10-Q · filed 2015-05-14 | $1.24M derived: sum of 4 quarters · filed 2015-09-25 |
| 2014-12-31 | $399.06K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-12 | $511.07K 10-Q · filed 2015-02-12 | $562.22K derived: sum of 3 quarters · filed 2015-09-25 | $705.45K derived: sum of 4 quarters · filed 2015-09-25 |
| 2014-09-30 | $112.01K 10-Q · filed 2014-11-13 | $163.16K derived: sum of 2 quarters · filed 2015-09-25 | $306.39K derived: sum of 3 quarters · filed 2015-09-25 | |
| 2014-06-30 | $51.15K derived: 10-K 12 month − 10-Q 9 month · filed 2015-09-25 | $194.37K derived: sum of 2 quarters · filed 2015-09-25 | $195.23K 10-K · filed 2015-09-25 | |
| 2014-03-31 | $143.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-15 | $144.07K 10-Q · filed 2014-05-15 | ||
| 2013-12-31 | $852.00 10-Q · filed 2014-02-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |